Sarcomas: immune biomarker expression and checkpoint inhibitor trials
Sarcomas are a heterogenous group of cancers stemming from mesenchymal tissues, and can be classified into soft-tissue and bone sarcomas [1]. These broad tumor categories are further divided based on distinct morphology and genetic changes into more than 100 subtypes as defined by the World Health Organization [1]. While most sarcomas are detected as local tumors and treated with excisional surgery and radiation, metastasis will occur in up to 50% within the first five years (depending on the site, grade and subtype) [2].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Mayanne MT Zhu, Elahe Shenasa, Torsten O Nielsen Tags: Tumour Review Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | International Medicine & Public Health | Sarcomas | WHO